<abstract xmlns="http://www.w3.org/1999/xhtml"><p><bold>Background</bold>: Daclizumab is a humanized monoclonal antibody against the D-subunit (CD25) of the high-affinity interleukin (IL)–2 receptor, used for the treatment of relapsing-remitting multiple sclerosis with a large spectrum of cutaneous adverse reactions. <bold>Case presentation:</bold> We present the case of a middle-aged man treated with daclizumab for multiple sclerosis, who developed skin reactions difficult to evaluate. A 4 mm punch-biopsy was taken from the plantar area. Histological examination of the biopsy revealed hyperkeratosis and acanthosis but no parakeratosis, while a discrete inflammatory infiltrate was noticed around vessels in the dermis. Treatment with fluconazole 50 mg/day for 10 days, moisturizers, and grade I topical steroids was followed by slight improvement of the clinical picture. Treatment with daclizumab was not discontinued. <bold>Conclusion:</bold> The clinical efficacy and side effects of daclizumab have to be reported and confirmed in clinical practice in the following years. Any clinical report can contribute to validate the efficacy and risk of the drug’s administration. Any type of adverse skin reaction must be reported for clarifying the diagnosis.</p></abstract>

Background: Daclizumab is a humanized monoclonal antibody against the D-subunit (CD25) of the high-affinity interleukin (IL)–2 receptor, used for the treatment of relapsing-remitting multiple sclerosis with a large spectrum of cutaneous adverse reactions. Case presentation: We present the case of a middle-aged man treated with daclizumab for multiple sclerosis, who developed skin reactions difficult to evaluate. A 4 mm punch-biopsy was taken from the plantar area. Histological examination of the biopsy revealed hyperkeratosis and acanthosis but no parakeratosis, while a discrete inflammatory infiltrate was noticed around vessels in the dermis. Treatment with fluconazole 50 mg/day for 10 days, moisturizers, and grade I topical steroids was followed by slight improvement of the clinical picture. Treatment with daclizumab was not discontinued. Conclusion: The clinical efficacy and side effects of daclizumab have to be reported and confirmed in clinical practice in the following years. Any clinical report can contribute to validate the efficacy and risk of the drug’s administration. Any type of adverse skin reaction must be reported for clarifying the diagnosis.

Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis

Department of Dermatology, Nicolina Medical Center

“P. Poni” Research Institute, Romanian Academy

University of Medicine, Pharmacy, Science and Technology

Journal of Interdisciplinary Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis"}

Background: Daclizumab is a humanized monoclonal antibody against the D-subunit (CD25) of the high-affinity interleukin (IL)–2 receptor, used for the treatment...

Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis

Publicado en línea: 18 jul 2019

Páginas: 37 - 40

Recibido: 01 sept 2018

Aceptado: 12 dic 2018

DOI: https://doi.org/10.2478/jim-2018-0038

Palabras clave
daclizumab, skin lesions, multiple sclerosis

© 2019 Anca Chiriac et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis

Publicado en línea: 18 jul 2019

Páginas: 37 - 40

Recibido: 01 sept 2018

Aceptado: 12 dic 2018

DOI: https://doi.org/10.2478/jim-2018-0038

Palabras clavedaclizumab, skin lesions, multiple sclerosis

© 2019 Anca Chiriac et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Palabras clave
daclizumab, skin lesions, multiple sclerosis